MX364527B - Derivados de triazolona de piridinilo y piridinilo fusionado. - Google Patents

Derivados de triazolona de piridinilo y piridinilo fusionado.

Info

Publication number: MX364527B
Authority: MX; Mexico
Prior art keywords: pyridinyl; fused; formula; triazolone derivatives; compounds
Prior art date: 2013-03-11

Application number

MX2015011533A

Other languages

English (en)

Spanish (es)

Other versions

MX2015011533A (es

Inventor

Wang Haixia

David Lawson John

Sabat Mark

Scorah Nicholas

H Vu Phong

Smith Christopher

Original Assignee

Takeda Pharmaceuticals Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-11

Filing date

2014-03-10

Publication date

2019-04-30

2014-03-10 Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co

2016-02-03 Publication of MX2015011533A publication Critical patent/MX2015011533A/es

2019-04-30 Publication of MX364527B publication Critical patent/MX364527B/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

MX2015011533A 2013-03-11 2014-03-10 Derivados de triazolona de piridinilo y piridinilo fusionado. MX364527B (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201361776445P	2013-03-11	2013-03-11
PCT/US2014/022801 WO2014164558A1 (en)	2013-03-11	2014-03-10	Pyridinyl and fused pyridinyl triazolone derivatives

Publications (2)

Publication Number	Publication Date
MX2015011533A MX2015011533A (es)	2016-02-03
MX364527B true MX364527B (es)	2019-04-30

Family

ID=50543655

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2015011533A MX364527B (es)	2013-03-11	2014-03-10	Derivados de triazolona de piridinilo y piridinilo fusionado.

Country Status (42)

Country	Link
US (4)	US9402841B2 (pl)
EP (2)	EP3235814B1 (pl)
JP (2)	JP6271700B2 (pl)
KR (1)	KR102300612B1 (pl)
CN (1)	CN105121427B (pl)
AP (1)	AP2015008646A0 (pl)
AR (1)	AR095198A1 (pl)
AU (1)	AU2014249248B2 (pl)
BR (1)	BR112015020264B1 (pl)
CA (1)	CA2899948C (pl)
CL (1)	CL2015002370A1 (pl)
CR (1)	CR20150470A (pl)
CY (1)	CY1119356T1 (pl)
DK (1)	DK2970202T3 (pl)
DO (1)	DOP2015000184A (pl)
EA (1)	EA028584B1 (pl)
EC (1)	ECSP15042779A (pl)
ES (2)	ES2624439T3 (pl)
GE (1)	GEP201706778B (pl)
HK (2)	HK1220183A1 (pl)
HR (1)	HRP20170622T1 (pl)
HU (1)	HUE032720T2 (pl)
IL (1)	IL240353B (pl)
JO (1)	JO3377B1 (pl)
LT (1)	LT2970202T (pl)
MA (1)	MA38391B1 (pl)
ME (1)	ME02693B (pl)
MX (1)	MX364527B (pl)
MY (1)	MY183927A (pl)
PE (1)	PE20151889A1 (pl)
PH (1)	PH12015502046B1 (pl)
PL (1)	PL2970202T3 (pl)
PT (1)	PT2970202T (pl)
RS (1)	RS55879B1 (pl)
SG (1)	SG11201506112QA (pl)
SI (1)	SI2970202T1 (pl)
TN (1)	TN2015000342A1 (pl)
TW (1)	TWI637950B (pl)
UA (1)	UA114944C2 (pl)
UY (1)	UY35376A (pl)
WO (1)	WO2014164558A1 (pl)
ZA (1)	ZA201505996B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE044146T2 (hu)	2012-09-10	2019-09-30	Principia Biopharma Inc	Pirazolopirimidin vegyületek mint kináz inhibitorok
JO3377B1 (ar) *	2013-03-11	2019-03-13	Takeda Pharmaceuticals Co	مشتقات بيريدينيل وبيريدينيل مندمج
PT3107544T (pt)	2014-02-21	2021-01-05	Principia Biopharma Inc	Sais e forma sólida de um inibidor de btk
CN104447530A (zh) *	2014-12-11	2015-03-25	苏州欧凯医药技术有限公司	4-甲基-2,6-二羧基吡啶的制备方法
PL3233103T3 (pl) *	2014-12-18	2021-04-19	Principia Biopharma Inc.	Leczenie pęcherzycy
WO2016210165A1 (en)	2015-06-24	2016-12-29	Principia Biopharma Inc.	Tyrosine kinase inhibitors
EA039213B1 (ru) *	2015-12-24	2021-12-17	Такеда Фармасьютикал Компани Лимитед	Сокристалл, способ его получения и лекарственное средство, содержащее сокристалл
WO2017122175A1 (en) *	2016-01-13	2017-07-20	Acerta Pharma B.V.	Therapeutic combinations of an antifolate and a btk inhibitor
CN109071496B (zh) *	2016-03-31	2021-07-30	武田药品有限公司	异喹啉基三唑酮复合物
CA3028169A1 (en)	2016-06-29	2018-01-04	Principia Biopharma Inc.	Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
EP3827008B1 (en)	2018-07-25	2024-07-31	Novartis AG	Nlrp3 inflammasome inhibitors
CN114364798A (zh)	2019-03-21	2022-04-15	欧恩科斯欧公司	用于治疗癌症的Dbait分子与激酶抑制剂的组合
JP2022527980A (ja) *	2019-04-02	2022-06-07	延世大学校産学協力団	新規化合物およびこれを有効成分として含む呼吸器疾患の予防または治療用組成物
AR119731A1 (es)	2019-05-17	2022-01-05	Novartis Ag	Inhibidores del inflamasoma nlrp3
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
JP7545570B2 (ja)	2020-08-14	2024-09-04	ノバルティスアーゲー	ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
AR130094A1 (es)	2022-08-03	2024-10-30	Novartis Ag	Inhibidores de inflamasoma nlrp3

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR0166088B1 (ko)	1990-01-23	1999-01-15	.	수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en)	1995-09-15	1995-11-15	Pfizer Ltd	Pharmaceutical formulations
US5733849A (en) *	1996-03-15	1998-03-31	Rohm And Haas Company	Halopyridyl triazolinone herbicides and herbicidal use thereof
GB9711643D0 (en)	1997-06-05	1997-07-30	Janssen Pharmaceutica Nv	Glass thermoplastic systems
MXPA00010150A (es)	1998-04-17	2002-05-14	Parker Hughes Inst	Inhibidores de btk y metodos para su identificacion y uso.
IL154784A0 (en) *	2000-09-15	2003-10-31	Vertex Pharma	Pyrazole derivatives and pharmaceutical compositions containing the same
HUP0303538A2 (hu)	2000-12-21	2005-02-28	Bristol-Myers Squibb Co.	Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények
US7572809B2 (en) *	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
WO2007087068A2 (en)	2006-01-13	2007-08-02	Pharmacyclics, Inc.	Inhibitors of tyrosine kinases and uses thereof
AU2007267859B2 (en) *	2006-05-25	2012-04-12	Synta Pharmaceuticals Corp.	Triazole compounds that modulate Hsp90 activity
WO2007147771A2 (en)	2006-06-20	2007-12-27	F. Hoffmann-La Roche Ag	Tetralin and indane derivatives and uses thereof
AR063946A1 (es)	2006-09-11	2009-03-04	Cgi Pharmaceuticals Inc	Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
HUE033182T2 (en)	2006-09-22	2017-11-28	Pharmacyclics Llc	Bruton tyrosine kinase inhibitors
EP2561875A3 (en)	2007-03-28	2013-06-12	Pharmacyclics, Inc.	Inhibitors of bruton's tyrosine kinase
CA2708361C (en)	2007-12-14	2016-06-07	F. Hoffmann-La Roche Ag	Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
AU2009211514B2 (en)	2008-02-05	2014-02-20	F. Hoffmann-La Roche Ag	Novel pyridinones and pyridazinones
RU2500680C2 (ru)	2008-06-24	2013-12-10	Ф.Хоффманн-Ля Рош Аг	Новые замещенные пиридин-2-оны и пиридазин-3-оны
ES2420854T3 (es)	2008-07-02	2013-08-27	F. Hoffmann-La Roche Ag	Nuevas fenilpirazinonas como inhibidores de quinasas
CA2726460C (en)	2008-07-15	2017-02-21	F. Hoffmann-La Roche Ag	Novel phenyl-imidazopyridines and pyridazines
US8598174B2 (en)	2008-11-12	2013-12-03	Genetech, Inc.	Pyridazinones, method of making, and method of use thereof
WO2010068788A1 (en) *	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Heterocyclic amides as btk inhibitors
WO2010068810A2 (en)	2008-12-10	2010-06-17	Cgi Pharmaceuticals, Inc.	Certain substituted amides, method of making, and method of use thereof
JP2013526546A (ja)	2010-05-13	2013-06-24	アムジエン・インコーポレーテツド	Ｐｄｅ１０阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
WO2011153553A2 (en)	2010-06-04	2011-12-08	The Regents Of The University Of California	Methods and compositions for kinase inhibition
AR083267A1 (es) *	2010-10-04	2013-02-13	Novartis Ag	Combinaciones farmaceuticas
CA2815131C (en)	2010-10-20	2020-06-09	Gruenenthal Gmbh	Substituted 6-amino-nicotinamides as kcnq2/3 modulators
JP2013544321A (ja)	2010-11-10	2013-12-12	エスティーシー．ユーエヌエム	ゼロ原子価金属粒子用エアロゾル還元／膨張合成（ａ−ｒｅｓ）
JO3377B1 (ar) *	2013-03-11	2019-03-13	Takeda Pharmaceuticals Co	مشتقات بيريدينيل وبيريدينيل مندمج

2014
- 2014-03-05 JO JOP/2014/0070A patent/JO3377B1/ar active
- 2014-03-10 SG SG11201506112QA patent/SG11201506112QA/en unknown
- 2014-03-10 ES ES14719130.8T patent/ES2624439T3/es active Active
- 2014-03-10 US US14/203,366 patent/US9402841B2/en active Active
- 2014-03-10 UY UY0001035376A patent/UY35376A/es not_active Application Discontinuation
- 2014-03-10 BR BR112015020264-0A patent/BR112015020264B1/pt active IP Right Grant
- 2014-03-10 ES ES17152008T patent/ES2714166T3/es active Active
- 2014-03-10 PL PL14719130T patent/PL2970202T3/pl unknown
- 2014-03-10 MY MYPI2015703082A patent/MY183927A/en unknown
- 2014-03-10 CA CA2899948A patent/CA2899948C/en active Active
- 2014-03-10 RS RS20170414A patent/RS55879B1/sr unknown
- 2014-03-10 JP JP2016501072A patent/JP6271700B2/ja active Active
- 2014-03-10 PE PE2015001905A patent/PE20151889A1/es active IP Right Grant
- 2014-03-10 AR ARP140100805A patent/AR095198A1/es active IP Right Grant
- 2014-03-10 GE GEAP201413953A patent/GEP201706778B/en unknown
- 2014-03-10 UA UAA201507597A patent/UA114944C2/uk unknown
- 2014-03-10 WO PCT/US2014/022801 patent/WO2014164558A1/en active Application Filing
- 2014-03-10 CN CN201480012902.5A patent/CN105121427B/zh active Active
- 2014-03-10 DK DK14719130.8T patent/DK2970202T3/en active
- 2014-03-10 AU AU2014249248A patent/AU2014249248B2/en active Active
- 2014-03-10 AP AP2015008646A patent/AP2015008646A0/xx unknown
- 2014-03-10 HU HUE14719130A patent/HUE032720T2/en unknown
- 2014-03-10 SI SI201430203A patent/SI2970202T1/sl unknown
- 2014-03-10 TW TW103108214A patent/TWI637950B/zh active
- 2014-03-10 MX MX2015011533A patent/MX364527B/es active IP Right Grant
- 2014-03-10 ME MEP-2017-98A patent/ME02693B/me unknown
- 2014-03-10 KR KR1020157028600A patent/KR102300612B1/ko active IP Right Grant
- 2014-03-10 EP EP17152008.3A patent/EP3235814B1/en active Active
- 2014-03-10 LT LTEP14719130.8T patent/LT2970202T/lt unknown
- 2014-03-10 PT PT147191308T patent/PT2970202T/pt unknown
- 2014-03-10 MA MA38391A patent/MA38391B1/fr unknown
- 2014-03-10 EP EP14719130.8A patent/EP2970202B1/en active Active
- 2014-03-10 EA EA201591686A patent/EA028584B1/ru unknown
2015
- 2015-08-04 IL IL240353A patent/IL240353B/en active IP Right Grant
- 2015-08-06 DO DO2015000184A patent/DOP2015000184A/es unknown
- 2015-08-11 TN TN2015000342A patent/TN2015000342A1/en unknown
- 2015-08-19 ZA ZA2015/05996A patent/ZA201505996B/en unknown
- 2015-08-24 CL CL2015002370A patent/CL2015002370A1/es unknown
- 2015-09-10 PH PH12015502046A patent/PH12015502046B1/en unknown
- 2015-09-10 CR CR20150470A patent/CR20150470A/es unknown
- 2015-10-08 EC ECIEPI201542779A patent/ECSP15042779A/es unknown
2016
- 2016-06-29 US US15/197,051 patent/US9801872B2/en active Active
- 2016-07-12 HK HK16108174.3A patent/HK1220183A1/zh unknown
2017
- 2017-04-20 HR HRP20170622TT patent/HRP20170622T1/hr unknown
- 2017-04-25 CY CY20171100458T patent/CY1119356T1/el unknown
- 2017-09-27 US US15/717,624 patent/US10307414B2/en active Active
- 2017-12-27 JP JP2017252294A patent/JP6462842B2/ja active Active
2018
- 2018-04-06 HK HK18104553.1A patent/HK1245256B/zh unknown
2019
- 2019-04-03 US US16/374,430 patent/US20190224190A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT2970202T (pt)	2017-05-03
DK2970202T3 (en)	2017-05-08
EA028584B1 (ru)	2017-12-29
TN2015000342A1 (en)	2017-01-03
HK1220183A1 (zh)	2017-04-28
JP6462842B2 (ja)	2019-01-30
HUE032720T2 (en)	2017-10-30
CA2899948C (en)	2021-11-16
JP2018076357A (ja)	2018-05-17
JO3377B1 (ar)	2019-03-13
AP2015008646A0 (en)	2015-08-31
RS55879B1 (sr)	2017-08-31
MA38391B1 (fr)	2018-09-28
ES2714166T3 (es)	2019-05-27
TWI637950B (zh)	2018-10-11
CL2015002370A1 (es)	2016-03-11
AU2014249248A1 (en)	2015-08-20
CY1119356T1 (el)	2018-02-14
IL240353A0 (en)	2015-09-24
MY183927A (en)	2021-03-17
TW201522328A (zh)	2015-06-16
KR20150126687A (ko)	2015-11-12
AU2014249248B2 (en)	2017-08-17
UA114944C2 (uk)	2017-08-28
LT2970202T (lt)	2017-06-12
CA2899948A1 (en)	2014-10-09
WO2014164558A1 (en)	2014-10-09
MA38391A1 (fr)	2018-01-31
CN105121427B (zh)	2018-04-10
HK1245256B (zh)	2019-09-27
GEP201706778B (en)	2017-11-27
ZA201505996B (en)	2016-11-30
US9402841B2 (en)	2016-08-02
ME02693B (me)	2017-10-20
PE20151889A1 (es)	2015-12-26
EP2970202B1 (en)	2017-02-01
EA201591686A1 (ru)	2015-12-30
US20180015083A1 (en)	2018-01-18
EP2970202A1 (en)	2016-01-20
ECSP15042779A (es)	2017-08-31
EP3235814B1 (en)	2018-12-12
US20140256734A1 (en)	2014-09-11
CN105121427A (zh)	2015-12-02
JP2016512515A (ja)	2016-04-28
NZ710852A (en)	2020-12-18
PH12015502046A1 (en)	2016-01-18
HRP20170622T1 (hr)	2017-06-30
US20160310483A1 (en)	2016-10-27
MX2015011533A (es)	2016-02-03
UY35376A (es)	2014-10-31
IL240353B (en)	2018-11-29
JP6271700B2 (ja)	2018-01-31
BR112015020264B1 (pt)	2021-03-02
CR20150470A (es)	2016-01-11
BR112015020264A2 (pt)	2017-07-18
US10307414B2 (en)	2019-06-04
ES2624439T3 (es)	2017-07-14
SG11201506112QA (en)	2015-09-29
SI2970202T1 (sl)	2017-07-31
US9801872B2 (en)	2017-10-31
PH12015502046B1 (en)	2016-01-18
PL2970202T3 (pl)	2017-08-31
DOP2015000184A (es)	2015-11-30
US20190224190A1 (en)	2019-07-25
KR102300612B1 (ko)	2021-09-09
AR095198A1 (es)	2015-09-30
EP3235814A1 (en)	2017-10-25

Publication	Publication Date	Title
PH12015502046A1 (en)	2016-01-18	Pyridinyl and fused pyridinyl triazolone derivatives
PH12016501972B1 (en)	2016-12-19	Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
TW201613593A (en)	2016-04-16	Molecules for administration to ROS1 mutant cancer cells
PH12015502615B1 (en)	2016-02-29	Chemical compounds
PH12015500063A1 (en)	2015-03-02	Azaindole derivatives which act as pi3k inhibitors
MX2015012006A (es)	2015-12-01	Inhibidores de bromodominio tetraciclicos.
MY193728A (en)	2022-10-27	Muscarinic receptor agonists
PH12017500163A1 (en)	2017-07-10	Optionally fused heterocyclyl - substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
PH12016501624A1 (en)	2016-11-07	1,2-substituted cyclopentanes as orexin receptor antagonists
TR201900148T4 (tr)	2019-02-21	Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX2017001603A (es)	2017-09-07	Derivados de piperazina como moduladores de los receptores x del higado.
MX2016009621A (es)	2016-11-17	Derivados de fur0-3-carboxamida y metodos de uso.
MX2015001657A (es)	2015-04-08	Compuestos de cianopirazol substituidos con receptores de acido lisofosfatidico (lpar).
MX2018004696A (es)	2018-11-29	Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
PH12017501134A1 (en)	2017-11-27	Fumagillol derivatives
MA40553A (fr)	2017-06-14	Dérivés de pyrimidine substitués par un hétérocyclyle éventuellement condensés utiles pour le traitement des maladies inflammatoires, métaboliques, oncologiques et auto-immunes

Legal Events

Date	Code	Title	Description
2019-04-30	FG	Grant or registration